Eculizumab Therapy for Subclinical Antibody-mediated Rejection in Kidney Transplantation

NCT02113891 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped disengagement of the sponsor Alexion Pharmaceuticals

Conditions

Subclinical Acute Antibody-mediated Rejection in Kidney Transplantation

Interventions

DRUG: Eculizumab

Sponsor

Assistance Publique - Hôpitaux de Paris

Collaborators

[object Object]
[object Object]
[object Object]